专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240374709A1 VACCINE COMPOSITIONS 审中-公开
公开(公告)号：US20240374709A1
公开(公告)日：2024-11-14
申请号：US18690650
申请日：2022-09-15
申请人： EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
发明人： James Paul LATA , Kelly Lyn WARFIELD , Michael Joseph LACY , Jee Loon LOOK , Christian Fernando RUIZ
IPC分类号： A61K39/145 , A61K39/00 , A61K39/39 , A61K47/02 , A61K47/18 , A61K47/26 , A61P37/04
CPC分类号： A61K39/145 , A61K39/39 , A61K47/02 , A61K47/18 , A61K47/26 , A61P37/04 , A61K2039/55505 , A61K2039/55561 , A61K2039/70
摘要： The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.

2. 发明申请

US20130115234A1 Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof 审中-公开
标题翻译：流感基质2蛋白，表达系统及其用途的胞外结构域
公开(公告)号：US20130115234A1
公开(公告)日：2013-05-09
申请号：US13637305
申请日：2011-03-28
申请人： Tina Guina , Michael Lacy , Mario Skiadopoulos , Nutan Mytle
发明人： Tina Guina , Michael Lacy , Mario Skiadopoulos , Nutan Mytle
IPC分类号： A61K39/145
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5256 , A61K2039/543 , C07K14/005 , C12N2710/24143 , C12N2760/16122 , C12N2760/16134
摘要： The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.
摘要翻译：本发明提供了多核苷酸，多肽，重组修饰的痘苗病毒安卡拉（rMVA）以及可用于预防和治疗流感病毒感染的相关疫苗组合物和方法。提供了编码M2流感胞外域多肽或包含该多核苷酸的rMVA的多拷贝的分离的多核苷酸。还提供了诱导针对流感病毒的受试者的免疫应答或用于治疗由流感病毒感染引起或由其感染的疾病或症状的方法。

3. 发明授权

US07537772B1 Chlamydia protein, gene sequence and the uses thereof 失效
标题翻译：衣原体蛋白，基因序列及其用途
公开(公告)号：US07537772B1
公开(公告)日：2009-05-26
申请号：US09677752
申请日：2000-10-02
申请人： W. James Jackson
发明人： W. James Jackson
IPC分类号： A61K39/118 , A61K39/00 , A61K39/02 , A61K39/116 , A61K38/00
CPC分类号： C07K14/295 , A61K39/00 , A61K2039/53 , C07K2319/00
摘要： The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived thereof (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.
摘要翻译：本发明公开了衣原体PMPE和PMPI多肽，其衍生的多肽（PMP衍生的多肽），编码所述多肽的核苷酸序列，特异性结合PMP多肽和PMP衍生多肽的抗体以及对PMP多肽和PMP衍生的多肽特异的T细胞多肽。还公开了预防和治疗组合物，包括免疫原性组合物，例如包含PMP多肽或PMP衍生的多肽或其抗体的疫苗。本发明还公开了在动物中诱导对衣原体细胞，衣原体基因体和/或表达衣原体蛋白（例如感染衣原体的细胞）的细胞的免疫应答的方法。

4. 发明申请

US20090053292A1 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof 失效
标题翻译：卡他莫拉菌素，核酸序列及其用途
公开(公告)号：US20090053292A1
公开(公告)日：2009-02-26
申请号：US12004502
申请日：2007-12-21
申请人： Kenneth Tucker , Ulrich F. Tillmann
发明人： Kenneth Tucker , Ulrich F. Tillmann
IPC分类号： A61K9/127 , C07K14/195 , C12N1/20 , G01N33/543 , C12Q1/68 , C07K16/12 , A61K39/02
CPC分类号： C07K14/212 , A61K38/00 , A61K39/00 , A61K2035/11 , A61K2039/522 , A61K2039/523 , A61K2039/53 , C07K16/1214 , C07K2317/734
摘要： The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.
摘要翻译：本发明公开了卡他莫拉菌外膜蛋白多肽及其衍生的多肽（统称为“OMP21”），编码所述OMP21的核苷酸序列，以及特异性结合OMP21的抗体。还公开了包含预防或治疗组合物的药物组合物，其可以是包含OMP21，其抗体或其编码核苷酸的疫苗的免疫原性组合物。本发明另外公开了在动物，优选人类的方法中诱导对卡他莫拉菌和OMP21的免疫应答的方法以及在动物，优选人中诊断莫拉氏菌感染的方法及其试剂盒。

5. 发明授权

US07419807B2 Chlamydia protein, gene sequence and uses thereof 失效
标题翻译：衣原体蛋白，基因序列及其用途
公开(公告)号：US07419807B2
公开(公告)日：2008-09-02
申请号：US10701844
申请日：2003-11-04
申请人： W. James Jackson , John L. Pace
发明人： W. James Jackson , John L. Pace
IPC分类号： C12P21/08 , C12N5/12 , C07H21/04 , C07K16/00 , A61K39/118
CPC分类号： G01N33/56927 , A61K38/00 , A61K39/00 , C07K14/295 , C07K16/125 , G01N2333/295 , Y10S514/885 , Y10S514/931 , Y10S514/937 , Y10S530/811 , Y10S530/814 , Y10S530/82
摘要： A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.
摘要翻译：公开了衣原体的高分子量（“HMW”）蛋白，其氨基酸序列和特异性结合HMW蛋白的抗体以及编码该HMW蛋白的核酸序列。还公开了包含HMW蛋白，其片段或特异性结合HMW蛋白或其部分的抗体或编码HMW蛋白或其片段（包括疫苗）的核苷酸序列的预防和治疗组合物。

6. 发明申请

US20080145916A1 MORAXELLA CATARRHALIS OUTER MEMBRANE PROTEIN-106 POLYPEPTIDE, GENE SEQUENCE AND USES THEREOF 审中-公开
标题翻译： MORAXELLA CATARRHALIS外膜蛋白-106多肽，基因序列及其用途
公开(公告)号：US20080145916A1
公开(公告)日：2008-06-19
申请号：US11925586
申请日：2007-10-26
申请人： Kenneth Tucker , Laura Plosila
发明人： Kenneth Tucker , Laura Plosila
IPC分类号： C12N1/20 , C07K16/12
CPC分类号： C07K14/212 , A61K39/00 , A61K2039/505 , C07K16/1203 , C07K16/1214 , C07K16/1217 , C07K2317/73 , C07K2317/734 , Y02A50/396
摘要： The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.
摘要翻译：本发明公开了卡他莫拉菌外膜蛋白-106（OMP106）多肽，由其衍生的多肽（OMP106衍生多肽），编码所述多肽的核苷酸序列，以及特异性结合OMP106多肽和/或OMP106衍生多肽的抗体。还公开了免疫原性，预防性或治疗性组合物，包括疫苗，其包含OMP106多肽和/或OMP106衍生的多肽。本发明另外公开了在动物体内诱导针对卡他莫拉菌和卡他莫拉菌OMP106多肽和OMP106衍生多肽的免疫应答的方法。

7. 发明授权

US10357559B2 Temperature stable vaccine formulations 有权
公开(公告)号：US10357559B2
公开(公告)日：2019-07-23
申请号：US15108244
申请日：2014-12-23
申请人： EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
发明人： Jee Look , Christian Fernando Ruiz , Aaron Paul Miles , Richard William Welch
IPC分类号： A61K39/39 , A61K47/26 , A61K9/19 , A61K39/07 , A61K39/12 , A61K39/145 , C12N7/00 , A61K39/00
摘要： Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.

8. 发明申请

US20190105367A1 ANTIMICROBIAL 4-OXOQUINOLIZINES 审中-公开
公开(公告)号：US20190105367A1
公开(公告)日：2019-04-11
申请号：US16188877
申请日：2018-11-13
申请人： Emergent Product Development Gaithersburg Inc.
发明人： Jutta HEIM , Peter SCHNEIDER , Patrick ROUSSEL , Daniel MILLIGAN , Christian BARTELS , Glenn DALE
IPC分类号： A61K38/12 , A61K31/506 , A61K31/496 , A61K31/4709 , A61K31/4545 , A61K31/444 , C07D455/02 , A61K31/4375
摘要： This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

9. 发明授权

US07846451B2 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof 失效
标题翻译：卡他莫拉菌素，核酸序列及其用途
公开(公告)号：US07846451B2
公开(公告)日：2010-12-07
申请号：US12004502
申请日：2007-12-21
申请人： Kenneth Tucker , Ulrich F. Tillman
发明人： Kenneth Tucker , Ulrich F. Tillman
IPC分类号： A61K39/02 , C12P21/04 , C07H21/04 , C07K14/00
CPC分类号： C07K14/212 , A61K38/00 , A61K39/00 , A61K2035/11 , A61K2039/522 , A61K2039/523 , A61K2039/53 , C07K16/1214 , C07K2317/734
摘要： The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.
摘要翻译：本发明公开了卡他莫拉菌外膜蛋白多肽及其衍生的多肽（统称为“OMP21”），编码所述OMP21的核苷酸序列，以及特异性结合OMP21的抗体。还公开了包含预防或治疗组合物的药物组合物，其可以是包含OMP21，其抗体或其编码核苷酸的疫苗的免疫原性组合物。本发明另外公开了在动物，优选人类的治疗方法和动物，优选人类中诊断莫拉菌感染的方法及其试剂盒中诱导对卡他莫拉菌和OMP21的免疫应答的方法。

10. 发明授权

US07442373B2 Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax 失效
标题翻译：针对保护性抗原的抗体和用于被动免疫和治疗炭疽的方法
公开(公告)号：US07442373B2
公开(公告)日：2008-10-28
申请号：US11041318
申请日：2005-01-24
申请人： Jeanne Morrow, legal representative , Angray S. Kang , Fei Wang , Ivy Jiang , Ritsuko Sawada , Wolfgang Scholz
发明人： Phillip R. Morrow
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： C07K16/1278 , A61K39/40 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.
摘要翻译：提供了使用召回技术产生人抗体的高效方法。一方面，提供了对炭疽毒素特异性的人抗体。一方面，在SCID小鼠模型中使用预先暴露于炭疽毒素的人外周血细胞。该方法导致高的人抗体滴度，其主要是IgG同种型，并且其含有对所需抗原具有高特异性和亲和力的抗体。通过该方法产生的抗体可以治疗和预防用于预防或治疗暴露于炭疽的哺乳动物。因此，在一个实施方案中，提供了用作抵抗作为生物恐怖机制的机制释放的炭疽毒素的作用的预防或治疗剂。在一个实施方案中，还提供了用于预防和/或治疗炭疽感染的制剂和方法，其包含防止PA63七聚体组装的结合剂。还描述了诊断方法和确定炭疽污染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式